LOY-002 could become first-ever FDA-approved drug for lifespan extension in any species

A drug designed to extend the healthy lifespan of senior dogs has reached a significant milestone on its path toward FDA approval, bringing hope to dog owners worldwide who want more quality years with their ageing companions.

Loyal, a biotechnology animal health company, announced on 13 January that the FDA has accepted the Target Animal Safety (TAS) technical section of its conditional approval application for LOY-002, a daily pill that targets age-related metabolic dysfunction in dogs.

This acceptance marks the second of three major technical sections required for market launch. The FDA Centre for Veterinary Medicine previously granted the application a “Reasonable Expectation of Effectiveness” designation. Only the manufacturing section remains to be accepted before conditional approval can be considered.

A paradigm shift in veterinary medicine

If ultimately approved, LOY-002 would represent a fundamental shift in how veterinarians approach ageing in dogs—treating it as a modifiable condition rather than simply managing age-related diseases as they arise.

“The metabolic dysfunction that all dogs experience as they age is a critical risk factor for many of the health problems that impact senior dogs,” explained Brennen McKenzie, VMD, MSc, MA, director of veterinary medicine at Loyal. “By improving metabolic health, we believe LOY-002 will extend not only lifespan but healthspan—the time that dogs are healthy and still able to enjoy their favourite activities and time with their human family.”

Safety first

The TAS acceptance represents the FDA’s approval of LOY-002’s safety profile—a crucial hurdle for any preventive therapy given to otherwise healthy animals.

“As a veterinarian, what I care about most, especially when it involves preventive care, is safety,” said Ellen Ratcliff, DVM, vice president of clinical and veterinary medicine at Loyal. “The FDA’s sign-off on this submission is an important vote of confidence in our mission to develop safe and effective lifespan extension drugs for dogs.”

The safety submission included evidence from several scientific investigations, most notably a standard safety study conducted at 1x, 3x, and 5x dose strengths with no clinically significant adverse events observed at any dose level.

Real-world evidence

The application also drew on data from the ongoing STAY study, which completed patient enrolment in July 2025 with 1300 dogs at 70 veterinary clinics across the United States.

The study included dogs given LOY-002 for up to one year, encompassing patients with a variety of ongoing medical conditions and other treatments commonly seen in senior dogs. The FDA agreed that these data support the conclusion that LOY-002 is safe for its intended use.

“The dogs were closely monitored, including regular examinations and laboratory testing,” McKenzie noted. The comprehensive approach demonstrates Loyal’s commitment to ensuring the drug’s safety profile meets the high standards required for preventive therapies.

How it works

LOY-002 is designed as a prescription daily pill for dogs aged 10 years and older weighing at least 6.4 kilograms. Rather than treating specific diseases, the drug targets the underlying metabolic changes that contribute to ageing itself.

As dogs age, their metabolism changes, increasing the risk of numerous health problems. LOY-002 aims to address these metabolic shifts directly, potentially preventing or delaying the onset of age-related conditions.

Path to approval

With safety now accepted, only the manufacturing section remains before conditional approval can be considered. Loyal anticipates this final major technical section to be reviewed in 2027.

However, the company could receive conditional approval and launch the drug before full approval is complete. Full approval would follow after completion of the STAY study, which serves as the pivotal effectiveness trial required to support a future full New Animal Drug Application approval.

“Since founding Loyal six years ago, my goal has always been to get the first drug FDA approved for lifespan extension,” said Celine Halioua, founder and CEO of Loyal. “This safety acceptance brings us very close to achieving that vision. We are well on our way to bringing the first dog longevity drugs to market.”

Looking ahead

If approved, LOY-002 would make history as the FDA’s first drug approval for lifespan extension in any species. The drug has already received the first known safety acceptance for a lifespan extension drug from the FDA.

For dog owners, the potential approval represents hope for more years with their beloved companions – not just more years, but more healthy, active years filled with the joy and vitality that makes the human-canine bond so special.

The company expects to launch LOY-002 in the first half of 2026 if conditional approval is granted, offering vets a new tool in the quest to give our dogs longer, healthier lives.

LOY-002 is a prescription drug in development. Availability is subject to FDA approval. For more information about Loyal and their lifespan extension programmes, visit loyal.com.